PRL and cancer: PRL-secreting PitNET accounts for approximately 40% of all pituitary tumors; the resulting hyperprolactinemia may cause infertility, galactorrhea, neurological dysfunction due to mass effect or it may remain asymptomatic.62 Most patients with PRL-secreting PitNETs achieve biochemical control and radiographic tumor regression with pharmacologic treatment (dopamine agonists); TSR represents the next best option for patients intolerant or unresponsive to medical treatment, while RT is reserved for resistant or malignant tumors.62